# NIH Reporter #1R44HD122555-01

Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder

**Recipient:** ALPHAROSE THERAPEUTICS INC.

**Award Amount:** $313,208.00
**Ceiling:** $313,208.00

**Awarded:** September 17, 2026

**Identifier:** 1R44HD122555-01

NIH-funded project supporting AlphaRose Therapeutics’ development of antisense oligonucleotide therapy for HNRNPH2 neurodevelopmental disorder, with the goal of advancing a candidate toward clinical trials.

### Description

Fast-Track SBIR project to advance antisense oligonucleotide candidates toward an Investigational New Drug application. The project includes manufacturing and testing candidate ASOs, in vivo efficacy studies to select a lead, and planned follow-on manufacturing, safety, biodistribution, and IND preparation work.

[View original record](https://reporter.nih.gov/search/J7l2tQ4hHkqRePwGq3m5kA/project-details/11408035)